Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | 9M2R7 | — |
The sterile water diluent from a Merck MMR-Varicella vaccine was used to reconstitute the MENVEO Vaccine on 13 February 2025; The sterile water diluent from a Merck MMR-Varicella vaccine was used to reconstitute the MENVEO Vaccine on 13 February 2025; Extra dose administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 17-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number 9M2R7) for prophylaxis. On 13-FEB-2025, the patient received the 2nd dose of Menveo. On 13-FEB-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: The sterile water diluent from a Merck MMR-Varicella vaccine was used to reconstitute the MENVEO Vaccine on 13 February 2025), inappropriate dose of vaccine administered (Verbatim: The sterile water diluent from a Merck MMR-Varicella vaccine was used to reconstitute the MENVEO Vaccine on 13 February 2025) and extra dose administered (Verbatim: Extra dose administered). The outcome of the wrong solution used in drug reconstitution, inappropriate dose of vaccine administered and extra dose administered were unknown. Additional Information: GSK Receipt Date: 18-FEB-2025 The reporter was a medical assistant for a medical office. The sterile water diluent from a Merck MMR Varicella vaccine was used to reconstitute the Menveo vaccine on 13th February 2025 which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The MMR Varicella antigen was not involved. The diluent was baxter sterile water. This was the second Menveo dose for the patient no other adverse event reported which led to extra dose administered.